Market Overview

Auxilium Pharmaceuticals up Nearly 9% on Positive Top-Line Results

Auxilium Pharmaceuticals (NASDAQ: AUXL) is trading higher on the session following positive top-line phase 3 results. In IMPRESS I at 52 weeks, the co-primary endpoints met statistical significance with a 37.6% mean reduction in penile curvature deformity for XIAFLEX subjects.

Adrian Adams, Auxilium's Chief Executive Officer and President stated: "We believe that XIAFLEX, if approved for the treatment of Peyronie's Disease, has the clinical profile to become a potential breakthrough procedure. With its current indication in Dupuytren's contracture, positive topline clinical results in Peyronie's Disease, and development ongoing in Frozen Shoulder syndrome and cellulite, XIAFLEX represents a pipeline in a product with potential applications in multiple therapeutic areas that currently have limited options."

Auxilium Pharmaceuticals is currently trading at $20.48, a gain of $1.63 or 8.65%.

Posted-In: News FDA

 

Related Articles (AUXL)

Around the Web, We're Loving...

Get Benzinga's Newsletters